{"id":"W4405374803","doi":"10.1016/j.iotech.2024.100791","title":"162P EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; AstraZeneca; Genentech; Seagen; Institut Servier; INCLIVA Instituto de Investigación Sanitaria; Menarini Group; EMD Serono; Deutschen Konsortium für Translationale Krebsforschung; Sociedad Española de Oncología Médica; PharmaMar; Novartis Farmacéutica; Daiichi Sankyo Europe; European Society for Medical Oncology; Grifols; Fundación Científica Asociación Española Contra el Cáncer; Regeneron Pharmaceuticals; Natera; BeiGene; Les Laboratories Pierre Fabre; Exelixis; Revolution Medicines; Cancer Research UK; Ribon Therapeutics; Takeda Pharmaceuticals International; Array BioPharma; Gilead Sciences; Taiho Pharmaceutical; F. Hoffmann-La Roche; HORIZON EUROPE Framework Programme; Servier; Astellas Pharma; Samsung; Eisai; FibroGen; Bristol-Myers Squibb; Eli Lilly and Company; Institut National Du Cancer; Oncode Institute; American Society of Clinical Oncology; Foundation Medicine; Sierra Oncology; European Association for Cancer Research; Sanofi; Amgen; Pfizer; Celgene","keywords":"Bevacizumab; Nivolumab; Colorectal cancer; Medicine; Oncology; Internal medicine; Metastatic melanoma; Cancer research; Chemotherapy; Immunotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002227765,0.0005168622,0.001198845,0.001073171,0.0001901873,0.00004092457,0.0002768926,0.0004622713,0.000250192],"category_scores_gemma":[0.00009004131,0.0004037842,0.0001454798,0.001475761,0.0007857411,0.0001630134,0.0002723648,0.0008352286,0.0001468588],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002128832,"about_ca_system_score_gemma":0.0007492215,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005446671,"about_ca_topic_score_gemma":0.002082179,"domain_scores_codex":[0.9971133,0.00009665481,0.000665391,0.0008922256,0.0002776035,0.000954796],"domain_scores_gemma":[0.9988313,0.0001837146,0.0001407568,0.0005303727,0.0002204105,0.00009348745],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01106288,0.003625891,0.5973467,0.0005209036,0.002853531,0.006110671,0.003704112,0.000008434145,0.01246587,0.001597195,0.002140472,0.3585633],"study_design_scores_gemma":[0.06008506,0.07517342,0.4408072,0.001154752,0.002952659,0.003772751,0.007674575,0.0005256388,0.05265911,0.003043381,0.3496512,0.002500237],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762662,0.01510345,0.00001932993,0.002221068,0.0006417996,0.001420822,0.00008264675,0.0004746413,0.003770043],"genre_scores_gemma":[0.9958547,0.0004997787,0.001220943,0.0001687282,0.0000383392,0.000615173,0.0001049551,0.00008350657,0.001413929],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3560631,"threshold_uncertainty_score":0.9998414,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008630389719972233,"score_gpt":0.2672043473917885,"score_spread":0.2585739576718163,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}